Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0069

Payer / HTA meeting · Dr. Sven Nakamura

22 Mar 2026 · In person · Dr. Sven Nakamura, National Cancer Center Tokyo · MSL Mei Tanaka · Vantrexa

ReviewedVeeva CRMENG-0069—

Capture insight from this engagement

Location: National Cancer Center Tokyo
Therapeutic area: Oncology
Country: Japan
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: MTMei TanakaMSL, Oncology (Japan)
Product: Vantrexa (vantrelimab)

Topics discussed

Chemotherapy-free first line

Scientific content used

PD-L1 testing pathway infographic

Questions raised

Is there subgroup data for patients with untreated brain metastases?
How should grade 2 infusion reactions be managed without steroids?

Notes

Payer / HTA meeting with oncology pharmacist at National Cancer Center Tokyo. Discussed chemotherapy-free first line.

Insights captured (1)

Capture insight

INS-0080High
Chemotherapy-free first line
Chemotherapy-free first line: request for data reported by oncology pharmacist (JP).
Deduplicated

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 2
Depth of exchange: 3
Actionability: 5

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0069

Audit history (0)

All create, update and approval events for this record

No audit events in sample data